Product Focus: Latest RIQAS Programmes
Product Focus: Latest RIQAS Programmes

RIQAS is the largest international External Quality Assessment (EQA)/ Proficiency Testing (PT) scheme, with over 45,000 participants across 32 comprehensive programme options. Providing access to large, international peer groups you can be confident in the statistical validity of the results obtained.
In March 2016, we added eight new RIQAS EQA programmes to our already extensive portfolio. The new programmes included; CSF, Sweat Testing, Immunosuppressant drugs, Trace Elements in Serum, Trace Elements in Urine, Trace Elements in Blood, Anti-TSH Receptor (TRAb) and Cyfra 21-1.
Like all programmes the latest additions are designed to cover the full clinical decision range, reassuring clinicians and patients that the results released are accurate and reliable. The added benefit of monthly reporting supports the rapid identification of errors, this combined with a report turnaround of 24-72 hours from the submission deadline allows faster implementation of any necessary corrective actions, reducing the need for expensive and time consuming patient sample retests.
With Cycle 2 of the new programmes just around the corner we thought we would take this opportunity to explore what each programme has to offer.
Week 1- Trace Elements in Serum, Trace Elements in Urine, Trace Elements in Blood
RIQAS provide three trace element programmes designed for use in clinical and toxicology laboratories specialising in the testing of trace metals, heavy metals and minerals. Options are available for blood, serum and urine ensuring a matrix similar to that of the patient sample. Each programme will help ensure the accuracy of test results in patients who have experienced accidental or occupational exposure to such toxic metals
Main Features and Benefits;
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Week 2- CYFRA 21-1 & Anti-TSH Receptor
The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of the tumour marker CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.
Main Features and Benefits;
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Our dedicated Anti-TSH Receptor EQA programme is designed to supplement our general immunoassay programme by including the thyroid hormone Anti-TSH Receptor also known as TRAb.
Main Features and Benefits;
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Week 3 – CSF & Sweat Testing
The RIQAS Cerebrospinal Fluid EQA programme has been designed to monitor the performance of several analytes in CSF.
Main Features and Benefits;
- Liquid ready-to-use samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
The RIQAS Sweat Testing EQA programme has been designed to cover the analysis of Sweat Testing in clinical laboratories measuring the concentration of Chloride, Sodium and Conductivity in sweat, used in the testing of Cystic Fibrosis (CF).
Main Features and Benefits;
- Liquid ready-to-use samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Week 4 – RIQAS Immunosuppressant EQA programme
The RIQAS Immunosuppressant Drug EQA programme has been designed to cover the analysis of Cyclosporin, Everolimus, Sirolimus and Tacrolimus in clinical laboratories.
Main Features and Benefits;
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Archives
- June 2022
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014